Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06257758 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
A Phase 1 study, sponsored by Valerio Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT06257758 is a Phase 1 study that was terminated before completion, run by Valerio Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT06257758, a Phase 1 study, was terminated before completion, sponsored by Valerio Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two parts to this trial, part 1 and part 2. Part 1 of the trial aims to answer these questions: * The safety and tolerability of VIO-01 when it is given alone or in combination with other anti-cancer therapies. * The highest dose that people can take without having unacceptable side effects * How well your body tolerates the drug alone or in combination, how they are absorbed, and the effects they have on your disease. Part 2 of the trial will further test VIO-01's effect in participants with advanced HRRm or HRD+ solid tumors and HRRm/HRD+ recurrent ovarian cancer. Participants will follow a schedule of visits to the study site to have assessments done related to their health condition and to receive the trial treatment.
Interventions
- DRUG VIO-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2025-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06257758
The ClinicalTrials.gov registry entry for NCT06257758 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VIO-01 is the first listed.
NCT06257758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06257758 about?
NCT06257758 is a clinical study titled "A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors". The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two parts to this trial, part 1 and part 2. Part 1 of the trial aims to answer these questions: * The safe...
What is the current status of trial NCT06257758?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-01-10. Estimated completion is 2025-01-01.
What interventions are being tested in trial NCT06257758?
The interventions under investigation include: VIO-01 (DRUG).
Who is sponsoring clinical trial NCT06257758?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.